Chromosomal Disorders. The types of chromosomal disorders: structural, deletion or addition. Down's syndrome, Turner's syndrome, Klinefelter's syndrome, Patau syndrome. Hope this presentation will help you.
Chromosomal Disorders. The types of chromosomal disorders: structural, deletion or addition. Down's syndrome, Turner's syndrome, Klinefelter's syndrome, Patau syndrome. Hope this presentation will help you.
Here, Genetic disorder and chromosomal abnormality discussed briefly. *Types of the genetic disorder *briefly discussed on different genetic diseases *chromosomal anomaly i.e. structural and numerical anomaly. etc.
OBSTETRICS & GYNAECOLOGICAL NURSING
GENETIC COUNSELLING DURING PREGNANC
INTRODUCTION-
COUNSELLING-Counselling is consultation, mutual interchange of opinions, deliberating together.A process in which the counsellor assist the counselee .
Provides concrete, accurate information about inherited disorders.
Provides information about prognosis and follow up.
Discuss ways in which disease can be prevented.
Here, Genetic disorder and chromosomal abnormality discussed briefly. *Types of the genetic disorder *briefly discussed on different genetic diseases *chromosomal anomaly i.e. structural and numerical anomaly. etc.
OBSTETRICS & GYNAECOLOGICAL NURSING
GENETIC COUNSELLING DURING PREGNANC
INTRODUCTION-
COUNSELLING-Counselling is consultation, mutual interchange of opinions, deliberating together.A process in which the counsellor assist the counselee .
Provides concrete, accurate information about inherited disorders.
Provides information about prognosis and follow up.
Discuss ways in which disease can be prevented.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
2. Introduction
• It is named after John Langdon Down, the British physician
who described the syndrome in 1866.
• The condition was identified as chromosome 21 trisomy by
Jerome Lejejune in 1959.
• Down Syndrome(DS) is the leading chromosomal cause of
mental retardation
• It is the most frequently reported birth defect
(Massimini,2000).
3. • DS occurs in 1 in every 700 live births
• Increasing maternal and paternal age is a risk factor.
• It is caused by a genetic imbalance resulting in the presence of
an extra twenty-first chromosome, or trisomy 21, in all or most
of the body's cells.
4. • 95% of DS cases result from a failure of chromosome 21 to
split completely during formation of the egg or sperm
(nondisjunction).
• A gamete is a mature male or female germ cell (sperm or egg).
• When the abnormal gamete joins a normal one, the result is
three copies of chromosome 21.
• Down syndrome occurs in all human populations & analogous
effects have been found in other in species such as
chimpanzees and mice.
5. • Often D.S. associated with some impairment of cognitive
ability and physical growth.
• D.S. patient tend to have lower than average cognitive ability
and mild- moderate disabilities.
• Children with D.S. who have received family support,
enrichment therapies, tutoring have been known to graduate
from school & college.
• Very few have a severe to high degree of intellectual
disabilities.
6.
7. Clinical Features
• Common physical features of D.S. are-
• macroglosia(protruding and oversized tongue).
• Microgenia- abnormal small chin
• Flat nasal bridge
• Small oral cavity
• Short neck
• Almond shaped eyes caused by epicanthic fold of eyelids( formerly known
as Mongoloid fold)
• Joint laxity in all limbs specially in atlanto-axial joint
• The incidence of atlantoaxial instability (AAI) ranges from 15 to 20%
• (American Academy of Pediatrics).
• Shorter limbs.
• Single transverse palmar crease in one or both palms
8. • Poor muscle tone usually hypotonicity
• Larger than normal space between big toes & second toes
• They may have a broad head and very round face.
• Language skills shows difference between understanding and
expressing speech, may have delay speech.
• Adult D.S. have short stature- the average height for men is 5
feet 1 inch(157 cm), for women 4 feet 9 inches( 144 cm)
• Individuals with D.S are also at high risk of obesity as they
aged.
9. • Developmental findings include delayed development and
impaired motor control.
• Feeding problems may be evident at birth and may require
intervention.
• Musculoskeletal manifestations may include pes planus
(flatfoot).
• thoracolumbar scoliosis.
• Patellar and possibly atlantoaxial instability.
10. • Other impairments are-
• Sensory changes
• Loss of Bladder and Bowl control
• Increased loss of strength
• Decreased motor skills
• Visual impairments-cataract, nystagmus are common.
• Other health concerns are-
• Congenital Heart diseases,
• Recurrent ear infections,
• Thyroid dysfunction,
• obstructive sleep apnea.
11. Complications
• Individuals with Down syndrome have a higher risk for many
conditions.
• Approximately 40 to 66% of children with DS also have
congenital heart disease (Harris and Shea ;Marino and
Pueschel, 1996), may need to undergo major corrective
surgeries soon after birth or later in life, while minor health
problems requiring no therapy.
12. • Malignancies- hematological malignancies like leukemia are
common in individuals with D.S.
• Risk for acute lymphoblastic leukemia is at least 10 times
more common in DS and for the megakaryoblastic form
of Acute myelogenous leukemia is at least 50 times more
common in DS.
• Others are hypothyroidism, GI complications (Hirschsprung's
disease – absence of nerve cells which controls colon
movements), increased risk of development of epilepsy,
compression of spinal cord due to subluxation of atlanto- axial
joint.
13. Management
• Depends on particular manifestations of conditions-for
instance, baby with GI complications may need to undergo
major surgery to rectify the defect.
• Early childhood interventions should be involved from birth
itself so as to help, co-ordinate & plan effective strategies for
learning and development, which comprises-
• Physiotherapy-to achieve normal developmental milestones,
to improve muscle tone, prevention of orthopedic deformities.
• Speech therapy
• Occupational therapy